Global Kinase Inhibitors Market Insights Forecasts to 2030
- The Kinase Inhibitors market was valued at USD 57.2 Billion in 2021.
- The market is growing at a CAGR of 7.3% from 2022 to 2030
- The Global Kinase Inhibitors market is expected to reach USD 95.3 Billion by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The Global Kinase Inhibitors market is expected to reach USD 95.3 Billion by 2030, at a CAGR of 7.3% during the forecast period 2022 to 2030.The Global Kinase Inhibitors Market is expanding due to an increase in the incidence of cancer and other chronic diseases, a rise in cancer diagnosis awareness, and an increase in clinical trials for cancer therapy. Moreover, technical improvement in the pharmaceutical sector and increased investment in R&D for cancer therapy by pharmaceutical companies are also boosting market expansion.
Kinase inhibitors are a class of medications that block the action of enzymes called kinases by adding a phosphate group to protein so that function of kinase becomes disrupted. Kinases have a role in numerous cellular processes, such as cell division, proliferation, and apoptosis, and their blockage can have detrimental effects on a cell, leading to its death or impaired performance. So, these kinds of medications are most frequently utilised to treat a range of illnesses where this kind of disturbance is required to be present, including cancer, diabetes, and inflammation.
This research report categorizes the market for Kinase Inhibitors market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Kinase Inhibitors market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the Kinase Inhibitors market.
Global Kinase Inhibitors Market Report Coverage
|Market Size in 2021:||USD 57.2 Billion|
|Forecast Period 2021-2030 CAGR:||7.3%|
|2030 Value Projection:||USD 95.3 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||110|
|Segments covered:||By Product, By Application, By End-User, By Region, and COVID-19 Impact Analysis.|
|Companies Covered:||Novartis AG,Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd., Abbott, F. Hoffmann-La Roche Ltd. Pfizer Inc, Lupin, Takeda Pharmaceutical Company Limited, Akorn, Incorporated, Torrent Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC., Astellas Pharma Inc., Sierra Oncology, Inc.|
|Growth Drivers:||The Global Kinase Inhibitors Market is now expanding due to factors such as the rising incidence and frequency of many cancers and other chronic diseases, increased awareness of cancer diagnosis and treatment, and an ageing population.|
|Pitfalls & Challenges:||Credit portfolios have been negatively impacted by the COVID-19 outbreak.|
Get more details on this report -
Due to the rising demand for several innovative kinase inhibitors being used in human trials for cancer therapy, the Global Kinase Inhibitors Market is anticipated to rise significantly in the approaching years. The Global Kinase Inhibitors Market is now expanding due to factors such as the rising incidence and frequency of many cancers and other chronic diseases, increased awareness of cancer diagnosis and treatment, and an ageing population. Moreover, technological advancement in the pharmaceutical sector and increased investment in R&D to come up with prospective medications for cancer therapy by pharmaceutical companies are also boosting the market expansion.Also, throughout the course of the projection period, participants in the Global Kinase Inhibitors Market will have numerous opportunities due to a growth in the acceptance of kinase inhibitors for newer applications and an increase in the number of new products receiving regulatory authority clearance.
The Global Kinase Inhibitors Market is experiencing substantial growth restrictions due to increasing R&D expenses, convoluted approval procedures, and onerous government regulations. Moreover, the high development cost of medications leads to the higher market price of the drug post-approval. As a result, the price of the treatment has limited market expansion to some extent.
- In 2021, the non-receptor tyrosine kinase inhibitors is dominating the market with the largest market share.
On the basis of product, the market is segmented into Tyrosine kinase inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors, and Others. Among these, the non receptor tyrosine kinase inhibitors is dominating the market with the largest market share owing to their effectiveness in treating autoimmune and inflammatory skin conditions including rheumatoid arthritis. Due to patent expiration and the release of generic medications onto the market, the growth of the receptor tyrosine kinase inhibitors market is predicted to slow.
- In 2021, the Oncology segment is dominating the market with the largest market share.
On the basis of application, the market is bifurcated into Oncology, Inflammatory Diseases and Others. Among these, the oncology segment holds the largest market share and is going to continue its dominance over the forecast periodbecause there is a greater need for several new kinase inhibitors that are being tested on people to treat cancer. Additionally, growing the incidence and frequency of various cancers, and raising knowledge about cancer detection and treatment has further boosted the market expansion.
- In 2021, the Healthcare facilities segment accounted the largest market share over the forecast period.
On the basis of End-User, the market is segmented into Pharmaceutical Companies, Private and Government research institutes, Academic Institutes, Healthcare facilities, and Others. Among these, the healthcare facilities segment accounted the largest market share over the forecast period. The Global Kinase Inhibitors Market in the healthcare facilities sector is expanding as a result of rising demand for efficient cancer treatment pharmaceuticals and increased awareness of early cancer detection and diagnosis.
Regional Segment Analysis of the Kinase Inhibitors Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
North America accounts for the biggest revenue share in Global Kinase Inhibitors Market in 2020 and is predicted to keep its dominance throughout the forecast period. The increased investment in R&D efforts for the development of novel cancer treatments in the region, which has stable and well-established economies like the US and Canada, is primarily responsible for the revenue rise in the North American market.Furthermore, the Kinase Inhibitors Market is growing significantly due to the presence of top pharmaceutical businesses in the area. The United States has one of the highest cancer rates in the world, which is anticipated to fuel market expansion.
- In February 2021, Novartis received the Breakthrough Therapy designation (BTD) grant by the USFDA for asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), which was previously treated with two or more tyrosine kinase inhibitors (TKIs).
The report offers the appropriate analysis of the key organizations/companies involved within the global Kinase Inhibitors market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Novartis AG
- Endo International Inc
- Teva Pharmaceutical Industries Ltd
- Glenmark Pharmaceuticals Ltd
- Cipla Inc
- Dr Reddy's Laboratories Ltd
- F. Hoffmann-La Roche Ltd
- Pfizer Inc
- Takeda Pharmaceutical Company Limited
- Akorn, Incorporated
- Torrent Pharmaceuticals Ltd.
- Amneal Pharmaceuticals LLC.
- Astellas Pharma Inc.
- Sierra Oncology, Inc.
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2021 to 2030. Spherical Insights has segmented the global Kinase Inhibitors market based on the below-mentioned segments:
Kinase Inhibitors Market, By Product
- Tyrosine kinase Inhibitors
- Multikinase Inhibitors
Kinase Inhibitors Market, By Application
- Inflammatory Diseases
Kinase Inhibitors Market, By End Users
- Academic Institutes
- Healthcare Facilities
Kinase Inhibitors Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?